Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMelrose Regulatory News (MRO)

Share Price Information for Melrose (MRO)

Share Price is delayed by 15 minutes
Get Live Data
463.90    4.30 (0.94%)
Bid:
463.80
Ask:
464.00
Spread: 0.20 (0.043%)
Market Cap: £5.78b
MRO Live PriceLast checked at - London Stock Exchange

Intraday Melrose Share Chart

Share Buyback Programme

2 Oct 2023 07:00

RNS Number : 2600O
Melrose Industries PLC
02 October 2023
 

2 October 2023

 

MELROSE INDUSTRIES PLC (THE "COMPANY")

 

COMMENCEMENT OF £500 MILLION SHARE BUYBACK PROGRAMME

 

Share buyback programme

 

As part of its 2023 interim results announcement on 7 September 2023, the Company announced it was commencing early its share buyback programme at the beginning of October 2023, starting with a £500 million on-market buyback, to be conducted over 12 months (the "Programme"). 

 

In accordance with the Company's general authority to make market purchases of existing ordinary shares of 160/7 pence each in the capital of the Company ("Ordinary Shares") as granted by its shareholders at the Annual General Meeting held on 8 June 2023 (the "General Authority"), the Programme will purchase no more than 202,586,150 Ordinary Shares and up to a maximum aggregate consideration payable by the Company of £500 million. The Programme will commence on 2 October 2023 and will end no later than 1 October 2024. The continuation of the Programme beyond the conclusion of the Company's next Annual General Meeting (or, if earlier, the close of trading on 30 June 2024) will be subject to the Company obtaining fresh general authority from its shareholders at such Annual General Meeting.

 

It is intended that Ordinary Shares repurchased shall be either held in treasury or cancelled, in each case as notified to the market from time to time.  Cancelling those shares will reduce the share capital of the Company whilst holding Ordinary Shares in treasury will give the Company the ability to cancel or re-issue such Ordinary Shares at a later date. Any purchases of Ordinary Shares by Melrose in relation to the Programme will be conducted in accordance with the General Authority, any further approvals to repurchase shares as may be granted by its shareholders from time to time, the Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as amended and supplemented), and Chapter 12 of the Listing Rules.

 

Melrose has entered into irrevocable, non-discretionary instructions with Investec Bank plc ("Investec") and J.P. Morgan Securities plc (which conducts its UK investment banking business as JP Morgan Cazenove, "JP Morgan Cazenove") to conduct the Programme on its behalf and to make trading decisions under the Programme independently of Melrose. The Programme will not impact the Company's existing Ordinary Share dividend policy.

 

Enquiries:

Investor Relations:

+44 (0) 7974 974690

ir@melroseplc.net

Montfort Communications - Financial PR:

+44 (0) 20 3514 0897

Nick Miles miles@montfort.london

+44 (0) 7739 701634

Charlotte McMullen mcmullen@montfort.london

+44 (0) 7921 881 800

Investec - Corporate Broker:

+44 (0) 20 7597 5970

Carlton Nelson

 

JP Morgan Cazenove - Corporate Broker:

+44 (0) 20 7986 4000

Robert Constant

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSUAOKROKURRRA
Date   Source Headline
19th Jun 20237:00 amRNSHolding(s) in Company
16th Jun 20234:45 pmRNSDirectorate Change
16th Jun 20231:30 pmRNSHolding(s) in Company
14th Jun 20236:19 pmRNSDirector/PDMR Shareholding
13th Jun 20234:50 pmRNSHolding(s) in Company
9th Jun 202310:00 amRNSHolding(s) in Company
8th Jun 20231:15 pmRNSResult of AGM
2nd Jun 202310:30 amRNSHolding(s) in Company
18th May 20235:15 pmRNSDirector/PDMR Shareholding
18th May 20234:02 pmRNSDirector/PDMR Shareholding
17th May 20231:00 pmRNSCapital Markets Event & New 2025 Guidance
15th May 20237:00 amRNSHolding(s) in Company
11th May 20235:15 pmRNSHolding(s) in Company
10th May 20237:00 amRNSTrading Update & New Guidance
5th May 20237:00 amRNSHolding(s) in Company
4th May 20237:00 amRNSHolding(s) in Company
27th Apr 202311:05 amRNSHolding(s) in Company
25th Apr 20234:35 pmRNSAnnual Report and Notice of Annual General Meeting
21st Apr 20234:00 pmRNSPost-Offer Undertakings Announcement
20th Apr 202312:20 pmRNSHolding(s) in Company
20th Apr 202311:55 amRNSDirector/PDMR Shareholding
20th Apr 20238:14 amRNSCompletion of the demerger of Dowlais
18th Apr 202311:30 amRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSDirector Declaration
13th Apr 20235:30 pmRNSMelrose Industries
3rd Apr 20237:00 amRNSHolding(s) in Company
31st Mar 20234:00 pmRNSConfirmation of Post-Offer Undertakings
30th Mar 202311:45 amRNSResults of General Meeting
17th Mar 20235:15 pmRNSDirector Declaration
16th Mar 20232:00 pmRNSSecond Interim Dividend - Payment Date
6th Mar 20234:15 pmRNSHolding(s) in Company
3rd Mar 20234:10 pmRNSPublication of a Prospectus
3rd Mar 20234:00 pmRNSCirc re. Demerger Proposal
2nd Mar 20237:00 amRNSFinal Results
17th Feb 20235:00 pmRNSDirector Declaration
31st Jan 20239:45 amRNSHolding(s) in Company
20th Jan 202312:30 pmRNSHolding(s) in Company
19th Jan 20237:00 amRNSTrading Update & Capital Markets Event
9th Jan 20237:00 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSCapital Markets Event
16th Nov 20223:00 pmRNSDirector/PDMR Shareholding
15th Nov 20227:00 amRNSTrading Statement
4th Nov 20225:30 pmRNSDirector Declaration
31st Oct 20227:00 amRNSHolding(s) in Company
27th Oct 20225:37 pmRNSHolding(s) in Company
26th Oct 20225:00 pmRNSDirector/PDMR Shareholding
21st Oct 20229:45 amRNSHolding(s) in Company
17th Oct 20223:00 pmRNSHolding(s) in Company
10th Oct 20227:00 amRNSHolding(s) in Company
29th Sep 20224:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.